Indoco Remedies Limited

Indoco Remedies Limited

Indoco Remedies Limited has informed the Exchange regarding USFDA inspection at its manufacturing facility at Plant II (Sterile) located at Goa, where seven observations were noted in Form 483.

Indoco Remedies Limited

Indoco Remedies Limited has informed the Exchange about the execution of a Deed of Conveyance for the sale of its plot of land to Kalpataru Townships Private Limited for Rs. 64,00,00,000. The sale would not impact the company's business operations.

Indoco Remedies Limited

Indoco Remedies Limited has informed the Exchange about Newspaper Advertisement regarding Notice convening the 79th AGM and E-voting Information.

Indoco Remedies Limited

Indoco Remedies Limited has informed the Exchange regarding 'Business Responsibility & Sustainability report for the financial year 2025-2026'.

Indoco Remedies Limited

Indoco Remedies Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 17, 2026, along with the Annual Report 2025-2026.

Indoco Remedies Limited

Indoco Remedies Limited has informed the Exchange that the Record Date for the purpose of Dividend is 10-Sep-2026, and the Company has fixed Thursday, 10th September, 2026 as the cut-off date for the purpose of remote e-voting and e-voting during the AGM.

Indoco Remedies Limited

Indoco Remedies Limited has informed the Exchange about the publication of a newspaper advertisement for its 79th Annual General Meeting (AGM) to be held on September 17, 2026, through Video Conferencing (VC)/Other Audio-Visual Means (OAVM). The AGM notice and annual report for the financial year 2025-2026 will be available on the company's website and stock exchange websites.

Indoco Remedies Limited

Indoco Remedies Limited has informed the Exchange about the transcript of Earnings Conference Call held on 28th July, 2026, in respect of Unaudited Standalone and Consolidated Financial Results for the Quarter Ended 30th June, 2026.

Indoco Remedies Limited

Indoco Remedies Limited has published unaudited standalone and consolidated financial results for the quarter ended 30th June, 2026, showing a net profit of Rs. 8,232 lakhs and a total comprehensive income of Rs. 8,187 lakhs.

Indoco Remedies Limited

Indoco Remedies Limited has informed the Exchange about the link to the recording of their earnings conference call for the quarter ended 30th June, 2026, which is available on their website.

Indoco Remedies Limited

Indoco Remedies Limited has informed the Exchange regarding the appointment of Mr. Sudhir Kadam as Senior Management Personnel designated as Sr. Vice President (Human Capital) of the company, effective from July 28, 2026. The Board of Directors has also re-appointed Ms. Aditi Panandikar as a Managing Director of the Company for a period of 5 years commencing from February 15, 2027, subject to the approval of the Shareholders at the ensuing 79th Annual General Meeting.

Indoco Remedies Limited

Indoco Remedies Limited has informed the Exchange regarding the reappointment of Mrs ADITI PANANDIKAR as Managing Director of the company w.e.f. February 15, 2027, and the appointment of Mr. Sudhir Kadam as Senior Management Personnel.

Indoco Remedies Limited

Indoco Remedies Limited has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 40,897 lakhs and a net profit of Rs. 8,232 lakhs. The company has recognized a gain on sale of its Ophthalmic Business Division to Sunways (India) Private Limited as an exceptional item.

Indoco Remedies Limited

Indoco Remedies Limited has scheduled an earnings conference call for Q1 FY2026-2027 on July 28, 2026, to discuss unaudited financial results for the quarter ended June 30, 2026.

Indoco Remedies Limited

Indoco Remedies Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June, 2026.

Indoco Remedies Limited

Indoco Remedies Limited has informed the Exchange regarding the closure of the trading window due to the upcoming declaration of unaudited standalone and consolidated financial results for the quarter ended 30th June, 2026.

Indoco Remedies Limited

Indoco Remedies Limited has informed the Exchange regarding a press release dated Jun 26, 2026, titled "Indoco Remedies Goa Plant successfully clears Malta Medicines Authority audit". The company's manufacturing facility for solid oral dosage form (Plant I) located at Goa has received EU GMP certification from the Malta Medicines Authority confirming that it complies with the Good Manufacturing Practice requirements as referred in the EC Directive.